Stay updated with breaking news from Vstm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mizuho upgraded shares of Verastem (NASDAQ:VSTM – Get Rating) from a neutral rating to a buy rating in a research report released on Thursday, The Fly reports. Mizuho currently has $36.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $24.00. VSTM has been the topic of a number of […]
By Dean Seal Shares of Verastem are trading higher after the company's recent update on its ovarian cancer treatment turned Mizuho analysts bullish on the...
By Stephen Nakrosis Shares of Verastem were trading lower in Thursday's after-hours market following news the company plans to sell shares and pre-funded...
StockNews.com initiated coverage on shares of Verastem (NASDAQ:VSTM – Get Rating) in a research note issued to investors on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Other analysts have also issued reports about the stock. Cantor Fitzgerald restated an overweight rating on shares of Verastem in a research note on […]
StockNews.com assumed coverage on shares of Verastem (NASDAQ:VSTM – Get Rating) in a report released on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. VSTM has been the subject of a number of other reports. HC Wainwright decreased their price objective on Verastem from $3.00 to $2.00 in a report […]